Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Bristol-Myers Squibb (NY: BMY ) 54.32 -1.45 (-2.60%) Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 12,895,353 Open 55.88 Bid (Size) 54.28 (5) Ask (Size) 54.68 (8) Prev. Close 55.77 Today's Range 54.20 - 55.90 52wk Range 39.35 - 56.20 Shares Outstanding 2,222,113,553 Dividend Yield 4.20% Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Bristol Myers Squibb Stock Gets Relative Strength Rating Upgrade November 01, 2024 On Friday, Bristol Myers Squibb stock earned an upgrade to its Relative Strength (RS) Rating, from 62 to 79. Via Investor's Business Daily Bristol Myers Squibb Expects New Schizophrenia Treatment To Boost Long-Term Growth, Analysts Remain Cautious November 01, 2024 Bristol Myers Squibb's revenue was fueled by Growth Portfolio and Eliquis. Analysts anticipate an impact from Cobenfy and a robust neuropsych pipeline. Via Benzinga Performance YTD +2.96% +2.96% 1 Month +0.22% +0.22% 3 Month +14.14% +14.14% 6 Month +23.74% +23.74% 1 Year +2.84% +2.84% More News Read More Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review November 01, 2024 Via Investor's Business Daily Unpacking the Latest Options Trading Trends in Bristol-Myers Squibb October 23, 2024 Via Benzinga Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024 October 31, 2024 From Bristol Myers Squibb Via Business Wire Stocks Tumble, Nasdaq 100 Selloffs As Tech Giants Disappoint, Crypto Companies Plummet: What's Driving Markets Thursday? October 31, 2024 Via Benzinga Bristol Myers Squibb (BMY) Q3 2024 Earnings Call Transcript October 31, 2024 Via The Motley Fool Topics Earnings Exposures Financial Bristol Myers Squibb Boosts 2024 Outlook On Strong Demand For Blood Thinner Med, New Drugs Drive Q3 Profit October 31, 2024 Via Benzinga Bristol Myers Earnings Top Q3 Estimates; Pharma Giant Raises Guidance October 31, 2024 Via Investor's Business Daily Bristol Myers Squibb Reports Third Quarter Financial Results for 2024 October 31, 2024 From Bristol Myers Squibb Via Business Wire Markets Give Back Gains As Hovering Continues October 30, 2024 Via Talk Markets Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights October 30, 2024 Via Benzinga Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy October 30, 2024 Via Benzinga Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024 October 28, 2024 From Bristol Myers Squibb Via Business Wire What Lies In Store For Healthcare ETFs In Q3 Earnings? October 27, 2024 Via Talk Markets Topics ETFs 800% Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer Focused ImmunityBio October 23, 2024 Via Benzinga Why Is Evotec Stock Gaining Today? October 23, 2024 Via Benzinga Healthcare Sector Update: Choppy Days Are Here Again As Yields Rise October 22, 2024 Via Talk Markets Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up October 18, 2024 Via Investor's Business Daily Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside October 17, 2024 Via Benzinga Johnson & Johnson Beats Wall Street Estimates. Is It Time to Buy, Sell, or Hold? October 16, 2024 Via The Motley Fool Novocure Shoots Skyward, Reversing Setbacks, After FDA Approves Lung Cancer Treatment October 15, 2024 Via Investor's Business Daily Exposures Product Safety Johnson & Johnson Dividend Stock Analysis - Saturday, Oct. 12 October 12, 2024 Via Talk Markets Cancer-Focused Perspective Therapeutics Stock Trades Lower After Drug Study Report October 11, 2024 Via Benzinga Reviva Pharmaceuticals Schizophrenia Drug Demonstrates Strong Efficacy On Heels Of Bristol Myers, FDA Approval: Analyst October 07, 2024 Via Benzinga Exposures Product Safety Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
